Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function

Psychopharmacology

Volumn 112, Issue 1 Supplement, 1993, Pages

  Palfreyman, Michael G ^a   Schmidt, Christopher J ^a   Sorensen, Stephen M ^a   Dudley, Mark W ^a   Kehne, John H ^a   Moser, Paul ^a   Gittos, Maurice W ^a   Carr, Albert A ^a  

^a Merrell Dow Research Institute   (United States)

Author keywords

5 Hydroxytryptamine2 (5 HT2) receptors; 5 Hydroxytryptamine3 (5 HT3) receptors; Amphetamine; Behavior; Dopamine; Nucleus accumbens; Striatum; Substantia nigra; Ventral tegmental area

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPEROZIDE; CLOZAPINE; DOLASETRON MESILATE; DOPAMINE; FLUNITRAZEPAM; HALOPERIDOL; HOMOVANILLIC ACID; KETANSERIN; MEPYRAMINE; MESULERGINE; MUSCIMOL; PRAZOSIN; PRECLAMOL; QUINUCLIDINYL BENZILATE; RADIOLIGAND; RAUWOLSCINE; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; SPIPERONE; STRYCHNINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BEHAVIOR; BIOCHEMISTRY; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; ELECTROPHYSIOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MICRODIALYSIS; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMAL; BASAL GANGLIA DISEASES; BEHAVIOR, ANIMAL; DOPAMINE; ELECTROPHYSIOLOGY; FLUOROBENZENES; INDOLES; MALE; MICE; MICRODIALYSIS; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURONS; PIPERIDINES; QUINOLIZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0027205672     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF02245008     Document Type: Article

References (36)

1. A rapid and sensitive model for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding
2. Pharmacological characterization of benzodiazepine receptors in the brain
3. Histamine H1 receptors in brain labelled with [3H]mepyranine
4. Relationship between inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzyme reaction
5. [3H]Rauwolscine and [3H]yohimbine to rat cerebral and human platelet membranes: possible heterogeneity of α2-adrenoceptors
6. [3H]-Spiroperidol labels dopamine receptors in the pituitary and brain
7. Na+-Independent binding of [3H]GABA and [3H]muscimol to subcellular particles of neuronal primary cultures and whole brains
8. Evidence for the existence of a raphe projection to the substantia nigra in rat
9. Biochemical and behavioral effects of serotonin neurotoxins on the nigrostriatal dopamine system: comparison of injection sites
10. Effects of ICI169,369, a selective serotonin antagonist, in electrophysiological tests predictive of antipsychotic activity
11. Identification of presynaptic serotonin autoreceptors using a new ligand:3H-PAT
12. Binding characteristics of [3H]prazosin to rat brain α-adrenergic receptors
13. Serotonin axon terminals in the ventral tagmental area of the rat: same structure and synoptic input to dopaminergic neurons
14. Multiple affinity binding slotes of the sigma receptor: effect of GTP-binding protein modifying agents
15. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding
16. [3H]Ketanserin (R41468), a selective3H-ligand for serotonin2 receptor binding sites
17. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia
18. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values
19. The effect of acute and chronic LY 277359, a selective 5-HT3 receptor antagonist, on the number of spontaneously active midbrain dopamine neurons
20. 5-HT3 receptor antagonists and their potential in psychiatric disorders
21. Antipsychotic potential of 5-HT3 antagonists
22. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site
23. Autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors
24. Neurotoxicity of the psychedelic amphetamine, methylenedioxy-methamphetamine
25. Antagonism of the neurotoxicity due to a single administration of methylenedioxy/methamphetamine
26. 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxy-methamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by l-dopa
27. l-Dopa-potentiation of the serotonergic deficits due to a single administration of 3,4 methylene dioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats
28. Biochemical identification of the mammalian muscarinic cholinergic receptor
29. Effect of acute and chronic MDL 73,147EF, a 5HT3 antagonist, on A9 and A10 dopamine neurons
30. 5-HT2 antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis
31. Molecular pharmacology of 5-HT1D recognition sites: radioligand binding studies in human, pig and calf brain membranes Naunyn-Schmiedeberg's
32. Strychnine binding associated with glycine receptors of the central nervous system